The Food and Drug Administration warned that insulin pumps manufactured by Medtronic in 2012 may bring potential cybersecurity and health risks to patients, Nextgov reported Friday. According to a separate statement, other users may access a nearby MiniMed insulin pump wirelessly and manipulate its settings to cease or over-deliver insulin to patients.
FDA noted that these activities may lead to diabetic ketoacidosis or high blood sugar. FDA validated that 4,000 MiniMed users are affected by the issue and has partnered with distributors to confirm additional users of the insulin pumps. According to Pamela Reese, global communications director at Medtronic, the firm has notified customers of the concerns and clarified that the affected devices do not have the capacity for wireless updates.